Vassili Valayannopoulos

Vassili Valayannopoulos

Company: Decibel Therapeutics

Job title: Vice President, Head of Clinical Research & Development


Dr Valayannopoulos, M.D., Ph.D., MBA, is a physician scientist with 20+ years of experience in Rare Disease and Gene Therapy who held clinical and scientific leadership roles both in academia (Necker University Hospital, Paris) and industry (Genzyme, Sanofi, Ultragenyx, Decibel). He is currently the Vice President and Head of Clinical Research and Development, at Decibel Therapeutics, Boston, MA.


Exploring the Immune Response to AAV Gene Therapies in Immune Privileged Organs 11:30 am

Definition of an immune privileged organ Evading immune response in the eye (retina) and inner ear (cochlea) Opportunities for clinical applicationsRead more

day: Day 1 Track B AM

Clinical Safety Monitoring for AAV Gene Therapies 101 8:30 am

A major objective of early-phase clinical trials is the safety evaluation of a drug candidate. With gene therapies, a complex mixture of difficult-to-predict immediate hypersensitivity and delayed immune reactions can occurs from anywhere between minutes and months of administration. As such, it is vitally important to outline the immune monitoring strategies as part of your…Read more

day: Pre-Conference Day

A Hanson Wade Group Company

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.